Morgan Stanley lowered the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $166 from $183 and keeps an Overweight rating on the shares after the company reported Q1 results, including updating its expense guidance to reflect the recent Xyrem antitrust settlement and Chimerix acquisition. Retention of 2025 revenue guidance despite the weaker quarter “should provide some price support,” the analyst tells investors in a post-earnings note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Optimistic Growth Outlook for Jazz Pharmaceuticals Amid Strategic Product Focus and Pipeline Catalysts
- Positive Outlook for Jazz Pharmaceuticals: Buy Rating Affirmed Amid Strategic Moves and Upcoming Catalysts
- Jazz Pharmaceuticals: Buy Rating Affirmed Amid Growth Potential and Transformative Catalysts
- Jazz Pharmaceuticals Reports Q1 2025 Financial Results
- Optimistic Buy Rating for Jazz Pharmaceuticals Amid Growth Prospects and Strategic Positioning